BATF2 and neoplasm: Therefore, future drugs targeting the NES region of specific tumour suppressors, such as BATF2, characterised by abnormal cytoplasmic localisation and selective tumour‐suppressing capacity, may provide higher efficacy and safety for the precise treatment of CRC.